Lipella eliminates Series A Preferred Stock designation after all shares converted to common

LIPELLA PHARMACEUTICALS INC.

Filed Series A Elimination Certificate with Delaware Secretary of State on April 11, 2024.
All previously issued Series A Preferred Stock converted into common stock; no shares outstanding.
No further shares will be issued under the Series A designation.
Certificate became effective immediately upon filing.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

LIPELLA PHARMACEUTICALS INC.: Eliminated and canceled all designations, rights, preferences and limitations of Series A Preferred Stock (effective 2024-04-11).

Change: charter amendment
Effective: 2024-04-11

Exact text from the filing

On April 11, 2024, the Company filed an Elimination of Certificate of Designation of the Preferences, Rights and Limitations of Series A Preferred Stock (the “Series A Elimination Certificate”) with the Secretary of State of the State of Delaware, in order to eliminate and cancel all designations, rights, preferences and limitations of the shares of the Company’s Series A convertible preferred stock, par value $0.0001 per share (the “Series A Preferred Stock”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

LIPELLA PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001753926-24-000721

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.